最新临床试验：苹果酸卡博替尼对既往接受过依维莫司的局部进展性、转移性或不能通过手术切除的神经内分泌肿瘤患者的疗效

这是经美国国家癌症研究所NCI批准的一项多中心随机对照 III期临床试验，目的是研究苹果酸卡博替尼与安慰剂相比，对以前用依维莫司治疗，并扩散到附近的组织或淋巴结、或扩散到身体其他部位、或不能通过手术切除的神经内分泌肿瘤患者的疗效。苹果酸卡博替尼是一种被称为酪氨酸激酶抑制剂的化疗药物，它的靶向位点是特定的酪氨酸激酶受体，当其被阻断时，可能减缓肿瘤生长。

该临床试验在全美295家医院进行开展。

This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Trial IDs